Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01592370
Title Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

chronic myeloid leukemia

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

Therapies

Nivolumab

Ipilimumab

Lirilumab

Age Groups: adult
Covered Countries USA | ITA | FRA | BEL


No variant requirements are available.